心臟生物标记市场规模、份额和成长分析（按产品、应用、检测施行地点和地区划分）－2026-2033年产业预测

预计到 2024 年，心臟生物标记市场规模将达到 119.5 亿美元，到 2025 年将达到 134.7 亿美元，到 2033 年将达到 349.8 亿美元，在预测期（2026-2033 年）内，复合年增长率为 12.67%。

心臟生物标记是心臟压力或损伤时释放的重要血液成分，在心臟衰竭和心肌梗塞等心臟相关疾病的诊断和治疗中发挥着至关重要的作用。心血管疾病盛行率的上升、人们对早期诊断益处的认识不断提高、对个人化医疗的需求日益增长以及生物标记技术的进步，都推动了这些生物标誌物市场的发展。然而，挑战仍然存在，例如先进的生物标记检测高成本且缺乏标准化，这可能导致结果不一致。儘管存在这些障碍，但在持续的技术创新、对预防医学的高度重视以及医疗保健成本不断上涨的推动下，该市场仍呈现出成长动能。这为更有效的心臟护理解决方案创造了机会。

心臟生物标记市场驱动因素

人们对早期发现心臟病益处的认识不断提高，大大推动了心臟生物标记市场的成长。随着越来越多的人意识到早期识别心血管疾病的重要性，人们更加重视利用先进的诊断方法来预防疾病进展并降低医疗成本。此外，蛋白质体学和基因组学的进步使得制定针对个别生物标记物谱的个人化有效治疗方案成为可能，这进一步激发了人们对心臟生物标记解决方案的兴趣和投资。这种向预防性医疗策略的转变凸显了心臟生物标记在现代医学中的关键作用。

心臟生物标记市场面临的限制

由于新生物标记的检验过程漫长，需要大规模的纵向研究和临床试验，心臟生物标记市场面临许多挑战。这种漫长的检验过程可能会阻碍新生物标记的应用，进而抑制市场成长。此外，患者人口统计学特征和合併症等因素导致生物标记水平存在差异，进而造成结果不一致，进一步加剧了这个问题，影响了检测结果的可靠性。这些限制凸显了建立可靠生物标记的难度，也是限制心臟生物标记市场整体发展和扩张的主要阻碍因素。

心臟生物标记市场趋势

在心臟生物标记市场中，多生物标记检测组合的应用显着增长，这主要得益于人们越来越倾向于采用比传统单标记物检测更全面的评估方式。这些组合能够帮助医疗专业人员更全面地评估与压力、心臟损伤和发炎等因素相关的心血管风险。鑑于心臟疾病日益复杂，人们正在研究多生物标记检测方法在增强风险分层和改善患者预后方面的潜力，尤其是在单一生物标记可能无法提供足够资讯的困难病例中。这一趋势标誌着心臟护理领域正朝着个人化医疗的方向迈进。

目录

介绍

• 调查目标
• 定义
• 市场覆盖范围

调查方法

• 资讯收集
• 二手和一手资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

前景
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场动态
  • 司机
  • 机会
  • 抑制因素
  • 任务
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 技术分析
• 专利分析
• 价值链分析
• 监管分析

心臟生物标记市场（按产品划分）

• 肌钙蛋白
• CK-MB
• 肌红蛋白
• BNP 和 NT-proBNP
• 其他的

按应用分類的心臟生物标记市场

• 急性冠状动脉症候群
• 心肌梗塞
• 郁血性心臟衰竭
• 其他的

按检测地点分類的心臟生物标记市场

• 检查室检测
• 就地检验

按地区分類的心臟生物标记市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲（MEA）
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争格局

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市占率（2025 年）

主要企业简介

• Abbott
• QuidelOrtho Corporation
• Siemens AG
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Biomerieux SA
• Bio-Rad Laboratories, Inc.
• Randox Laboratories Ltd.
• Creative Diagnostics
• Life Diagnostics
• Thermo Fisher Scientific
• Becton, Dickinson and Company
• DiaSorin
• Myriad RBM
• Mindray Medical International Limited
• ReLIA Diagnostic Systems
• Merck KGaA
• Quanterix Corporation
• Eurofins Scientific
• Inova Diagnostics

结论与建议

Cardiac Biomarkers Market size was valued at USD 11.95 Billion in 2024 and is poised to grow from USD 13.47 Billion in 2025 to USD 34.98 Billion by 2033, growing at a CAGR of 12.67% during the forecast period (2026-2033).

Cardiac biomarkers are crucial blood components released during heart stress or damage, playing a vital role in diagnosing and managing heart-related conditions such as heart failure and myocardial infarction. The market for these biomarkers is propelled by the rising prevalence of cardiovascular diseases, heightened awareness around early diagnostic benefits, an increasing demand for personalized medicine, and advancements in biomarker technology. However, challenges remain, including the high costs associated with advanced biomarker testing and a lack of standardization, which can lead to inconsistencies in results. Despite these obstacles, the market is poised for growth, fueled by ongoing innovations, a strong focus on preventive healthcare, and escalating healthcare expenditures. This creates opportunities for more effective cardiac care solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cardiac Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cardiac Biomarkers Market Segments Analysis

Global Cardiac Biomarkers Market is segmented by Product, Application, Location of Testing, and Region. Based on Product, the market is segmented into Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others. Based on Application, the market is segmented into Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others. Based on Location of Testing, the market is segmented into Laboratory Testing, Point of Care Testing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cardiac Biomarkers Market

The rising awareness about the advantages of early detection of heart diseases has significantly contributed to the growth of the cardiac biomarkers market. As more individuals recognize the importance of identifying cardiovascular issues early, there is a heightened focus on utilizing advanced diagnostic methods to prevent disease progression and reduce healthcare expenses. Additionally, advancements in proteomics and genomics are facilitating the development of personalized and effective treatment plans tailored to individual biomarker profiles, further driving interest and investment in cardiac biomarker solutions. This shift towards proactive healthcare strategies underscores the critical role of cardiac biomarkers in modern medical practice.

Restraints in the Cardiac Biomarkers Market

The cardiac biomarkers market faces significant challenges due to the lengthy process required for validating novel biomarkers, which mandates extensive longitudinal studies and clinical trials. This lengthy validation process can hinder the introduction of new biomarkers, ultimately stunting market growth. Additionally, inconsistent results arising from variations in biomarker levels-attributed to factors such as patient demographics and comorbidities-further complicate the situation, affecting the reliability of test outcomes. These limitations underscore the difficulties in establishing dependable biomarkers, which poses a substantial restraint on the overall advancement and expansion of the cardiac biomarkers market.

Market Trends of the Cardiac Biomarkers Market

The cardiac biomarkers market is witnessing a notable shift towards the adoption of multi-biomarker panels, reflecting a growing preference for comprehensive evaluation over traditional single-marker testing. These panels enable healthcare professionals to conduct a more thorough assessment of cardiovascular risks associated with factors such as stress, cardiac injury, and inflammation. As the complexity of cardiac conditions increases, multi-biomarker approaches are being investigated for their potential to enhance risk stratification and improve patient outcomes, particularly in challenging cases where individual biomarkers may lack sufficient insight. This trend signifies a transformative movement towards personalized medicine in cardiac care.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Patent Analysis
• Value Chain Analysis
• Regulatory Analysis

Cardiac Biomarkers Market By Product

• Market Overview
• Troponin
• CK-MB
• Myoglobin
• BNP & NT-proBNP
• Others

Cardiac Biomarkers Market By Application

• Market Overview
• Acute Coronary Syndrome
• Myocardial Infarction
• Congestive Heart Failure
• Others

Cardiac Biomarkers Market By Location of Testing

• Market Overview
• Laboratory Testing
• Point of Care Testing

Cardiac Biomarkers Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2025

Key Company Profiles

• Abbott
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QuidelOrtho Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Life Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad RBM
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mindray Medical International Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ReLIA Diagnostic Systems
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quanterix Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inova Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation